The Landscape of lower respiratory tract herpesviruses in severe pneumonia patients: a multicenter, retrospective study with prospective validation
Performance · 28-day mortalityResult — go to the resultAdj-HR 1.439 95% CI 1.093–1.894Authors' conclusion
Co-detection of HSV-1 and CMV was associated with increased 28-day mortality.
Study context
- Population
- Severe pneumonia patients undergoing bronchoalveolar lavage fluid (BALF) metagenomic testing in ICUs, 17 centres, January 2019 to June 2023
- Participants
- 1,737 patients · 17 centres
- Comparison
- Herpesvirus-positive vs herpesvirus-negative
- Outcome
- 28-day mortality
- Follow-up
- 28 days
Methodological detailsmulticentre, propensity-score matched, multivariable Cox regression, interaction analyses
- Multicentre
- Propensity-score matched
- Multivariable Cox regression
- Interaction analyses
Performance
As reported in the abstract
Adj-HR
1.439
95% CI 1.093–1.894
P = 0.009
HSV-1 + CMV co-detection vs both negative
adj-HR 1.439 (95% CI 1.093–1.894); P = 0.009
Further findings
| Outcome | adj-HR (95% CI) | P value | |
|---|---|---|---|
| 28-day mortality, HSV-1 + CMV co-detection (prospective validation cohort) · 28 daysHSV-1 + CMV co-detection vs both negative | 1.656 (1.061–2.585) | P = 0.026 | |
| 0.20.5125Adj-HR (log scale) |
28-day mortality, overall cohort
- 28-day mortality rate
- 41.3% (718/1,737)
Herpesvirus detection frequencies
- Herpesviruses detected (patients)
- 828
- HSV-1
- 26.8%
- CMV
- 17.8%
- EBV
- 16.6%
- HHV-7
- 5.3%
- HHV-6B
- 2.2%
- VZV
- 0.5%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The Landscape of lower respiratory tract herpesviruses in severe pneumonia patients: a multicenter, retrospective study with prospective validation. Crit Care. Published 20 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →